For example, prevalence of advanced fibrosis in patients with elevated ALT and four concurrent metabolic co-morbidities is as high as 6.68%, and the prevalence of cirrhosis in patients with elevated ALT and four concurrent metabolic co-morbidities is as high as 2.81%. This evidence concerns the gene GPT and Cirrhosis.